Terumo to acquire drug product plant from WuXi Biologics for €150m.

Terumo, a company specializing in medical devices and CDMO services, agreed to acquire drug product plant from WuXi Biologics, a biopharmaceutical company, for €150m. "The acquisition of the drug product plant is a pivotal step in enhancing the competitiveness of our CDMO business, and we are thrilled to have reached an agreement with WuXi Biologics. By integrating the high-quality and stable production operations of the Leverkusen plant and the exceptional talent supporting it with Terumo, we are confident that we will significantly elevate the global responsiveness of our CDMO business," Hikaru Samejima, Terumo Corporation Chief Executive Officer.